Literature DB >> 10459788

The presentation, treatment and outcome of renal cell carcinoma in old age.

J G Doherty1, A Rüfer, P Bartholomew, D M Beaumont.   

Abstract

OBJECTIVE: To review clinical presentation and outcome of patients with a diagnosis of renal cell carcinoma at a district general hospital and assess whether older patients were more likely to present in a non-specific manner or receive more conservative management and whether their survival was less favourable. SUBJECTS AND METHODS: 39 patients presenting with a diagnosis of renal cell carcinoma between 1987 and 1995 were identified from hospital activity analysis data and histopathology records. We divided the subjects into young patients (< 69 years: n = 27) and elderly patients (>70 years: n = 10), and made a retrospective analysis of clinical features, laboratory results, pathology, staging, treatment and survival from hospital records.
RESULTS: Anaemia, hypertension and weight loss were common clinical features in both young and elderly groups. The prevalence of non-urological symptoms did not differ between study groups. Anaemia was frequently microcytic and hypochromic. Hypertension was present in 46% of patients and one-third of these were newly diagnosed. In 19% of patients with renal cell carcinoma, the diagnosis was made incidentally while imaging for other indications. Elderly patients were as likely to receive surgical treatment as younger patients. Survival differed with stage but not age.
CONCLUSIONS: Neither clinical presentation, management nor survival differed between the young and elderly subjects. Renal cell carcinoma should be considered in elderly patients with systemic features such as malaise or weight loss associated with anaemia, hypertension and raised erythrocyte sedimentation rate.

Entities:  

Mesh:

Year:  1999        PMID: 10459788     DOI: 10.1093/ageing/28.4.359

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  3 in total

1.  Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.

Authors:  Giovan Giuseppe Di Costanzo; Raffaella Tortora; Massimo De Luca; Alfonso Galeota Lanza; Filippo Lampasi; Maria Teresa Tartaglione; Francesco Paolo Picciotto; Michele Imparato; Silvana Mattera; Gabriella Cordone; Antonio Ascione
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

2.  Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.

Authors:  Tim Eisen; Stéphane Oudard; Cezary Szczylik; Gwenaelle Gravis; Hans Heinzer; Richard Middleton; Frank Cihon; Sibyl Anderson; Sonalee Shah; Ronald Bukowski; Bernard Escudier
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506

3.  Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

Authors:  T E Hutson; R M Bukowski; B I Rini; M E Gore; J M Larkin; R A Figlin; C H Barrios; B Escudier; X Lin; K Fly; B Martell; E Matczak; R J Motzer
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.